You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 9, 2024

Investigational Drug Information for Reparixin


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Reparixin?

Reparixin is an investigational drug.

There have been 14 clinical trials for Reparixin. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2022.

The most common disease conditions in clinical trials are Breast Neoplasms, Pneumonia, and COVID-19. The leading clinical trial sponsors are Dompé Farmaceutici S.p.A, PRA Health Sciences, and Icahn School of Medicine at Mount Sinai.

Recent Clinical Trials for Reparixin
TitleSponsorPhase
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)NovartisPhase 2
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)Icahn School of Medicine at Mount SinaiPhase 2
Add-on Reparixin in Adult Patients With ARDSDompé Farmaceutici S.p.APhase 2

See all Reparixin clinical trials

Clinical Trial Summary for Reparixin

Top disease conditions for Reparixin
Top clinical trial sponsors for Reparixin

See all Reparixin clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.